You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康諾亞-B(02162.HK):CMG901 Ia期臨牀研究數據最新結果在2023 ASCO GI上發表
格隆匯 01-18 08:02

格隆匯1月18日丨康諾亞-B(02162.HK)發佈公吿,其在研新藥CMG901(Claudin 18.2抗體偶聯藥物)治療晚期實體瘤的Ia期劑量遞增臨牀研究最新數據將在2023年美國臨牀腫瘤學會胃腸道腫瘤研討會(2023 ASCO GI)上以壁報形式發佈。

該Ia期研究(NCT04805307)的目標是評估CMG901在晚期實體瘤患者中的安全性、耐受性、藥代動力學指標、免疫原性及初步抗腫瘤活性。在劑量遞增階段,對患者Claudin 18.2的表達採用回顧性分析。 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account